Fecal Microbiota Transplantation Significantly Lowers Triglycerides and Raises HDL-C in Metabolic Syndrome Patients
Background
Metabolic syndrome (MetS) is a growing global health challenge characterized by a cluster of conditions including central obesity, high blood pressure, elevated blood sugar, and dyslipidemia. Impaired lipid metabolism, specifically high triglycerides and low high-density lipoprotein cholesterol (HDL-C), is a key feature contributing to cardiovascular risk. While fecal microbiota transplantation (FMT) shows promise by modulating the gut microbiome, existing meta-analyses have primarily focused on glycemic parameters, leaving its impact on lipid metabolism largely unexplored. This gap necessitates a systematic assessment of FMT's influence on lipid profiles in MetS patients.
Study Design
A comprehensive meta-analysis was conducted to evaluate the effect of allogenic FMT on lipid parameters in patients diagnosed with Metabolic Syndrome. Researchers systematically searched PubMed/Medline, EMBASE, Web of Science, Cochrane Library, and Scopus databases from inception until August 31, 2023, using terms related to FMT and MetS. The analysis included 9 randomized controlled trials (RCTs), encompassing a total of 248 patients. Primary endpoints assessed were changes in triglycerides (TG), total cholesterol (TCHO), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C). Subgroup analyses were performed based on follow-up durations to identify time-dependent effects.
Results
The meta-analysis of 9 RCTs involving 248 patients revealed significant improvements in key lipid markers following allogenic FMT. Patients receiving allogenic FMT exhibited significantly lower TG levels compared to control groups (receiving placebo or autologous FMT), with a pooled Mean Difference (MD) of -0.15 (95% CI: -0.29, -0.01). Concurrently, HDL-C levels were significantly higher in the FMT group, showing an MD of 0.07 (95% CI: 0.02, 0.12).
Key Findings
- Allogenic FMT significantly lowered triglyceride (TG) levels in MetS patients (pooled MD -0.15, 95% CI: -0.29, -0.01).
- Allogenic FMT significantly elevated high-density lipoprotein cholesterol (HDL-C) levels (pooled MD 0.07, 95% CI: 0.02, 0.12).
- These beneficial effects on TG and HDL-C were significant at 4 to 6 weeks post-FMT.
- No significant differences were observed in total cholesterol (TCHO) or low-density lipoprotein cholesterol (LDL-C) levels.
Why It Matters
This meta-analysis provides compelling evidence that allogenic fecal microbiota transplantation (FMT) can positively modulate lipid profiles in patients with metabolic syndrome, specifically by reducing triglycerides and increasing HDL-C. This finding is crucial as it highlights a potential non-pharmacological strategy to address dyslipidemia, a major cardiovascular risk factor in MetS, by targeting the gut microbiome. The practical takeaway is that FMT could emerge as an adjunctive therapy for lipid management in MetS, offering a novel approach beyond conventional medications. While promising, the optimal donor selection, preparation, and long-term efficacy of FMT protocols still require further investigation in larger, longer-duration RCTs before widespread clinical adoption. This research underscores the importance of the gut-microbiome in metabolic health and could influence future guidelines for MetS management.
fecal microbiota transplantation
fmt
metabolic syndrome
dyslipidemia
triglycerides
hdl-c